(PBH) Prestige Brand Holdings - Ratings and Ratios

Prestige Consumer Healthcare Inc. (NYSE:PBH) is a leading developer, manufacturer, and distributor of over-the-counter (OTC) health and personal care products. The company operates through two primary segments: North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio includes well-known brands such as BC, Goodys, Boudreauxs Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Fleet, Gaviscon, Ludens, Monistat, Nix, Summers Eve, TheraTears, Fess, and Hydralyte. These products address a wide range of healthcare needs, including pain relief, digestive health, feminine care, skincare, and oral rehydration. The company distributes its products through mass merchandisers, drugstores, food retailers, convenience stores, and e-commerce platforms. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York. The company rebranded from Prestige Brands Holdings, Inc. to Prestige Consumer Healthcare Inc. in August 2018 to better reflect its focus on consumer health products.

The companys product lineup includes analgesic powders, diaper rash treatments, sore throat sprays, eye care products, wart removal solutions, ear wax removal products, dental care accessories, motion sickness remedies, laxatives, antacids, cough drops, yeast infection treatments, lice treatments, feminine hygiene products, dry eye remedies, nasal saline sprays, and oral rehydration solutions. This broad range of offerings positions Prestige Consumer Healthcare Inc. as a key player in the OTC healthcare market, catering to both domestic and international markets.

Based on the provided data, here is a 3-month forecast:

Technical Outlook: The stock is currently trading below its 20-day and 50-day moving averages (SMA20: 81.97, SMA50: 83.85) but remains above its 200-day moving average (SMA200: 77.41). This indicates potential short-term weakness but longer-term bullish momentum. The Average True Range (ATR) of 2.33 suggests moderate volatility, which could lead to price swings in the near term.

Fundamental Outlook: With a market cap of $4.068 billion and a price-to-earnings (P/E) ratio of 19.28, the stock is trading at a premium compared to its forward P/E of 16.98, suggesting expectations of future earnings growth. The price-to-book (P/B) ratio of 2.24 indicates that the stock may be overvalued relative to its book value. The price-to-sales (P/S) ratio of 3.64 reflects a higher valuation compared to its revenue. Return on equity (RoE) of 11.96% highlights decent profitability.

3-Month Forecast: Expect the stock to consolidate near current levels, with potential support at $77.41 (SMA200) and resistance at $83.85 (SMA50). Earnings reports and macroeconomic conditions will likely influence short-term movements. If the company meets or exceeds forward earnings expectations, the stock could rebound toward its SMA50 level. Conversely, any negative surprises could push it toward its SMA200 support.